Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir
Contributeurs/tricesAnanworanich, Jintanat; Gayet-Ageron, Angèle; Ruxrungtham, Kiat; Chetchotisakd, Ploenchan; Prasithsirikul, Wisit; Kiertiburanakul, Sasisopin; Munsakul, Warangkana; Raksakulkarn, Phitsonu; Tansuphasawadikul, Somboon; LeBraz, Michelle; Jupimai, Thidarat; Ubolyam, Sasiwimol; Schutz, Malte; Hirschel, Bernard
Publié dansAntiviral therapy, vol. 13, no. 3, p. 375-380
Date de publication2008
Résumé
Mots-clés
- Adult
- Antiretroviral Therapy, Highly Active
- CD4 Lymphocyte Count
- Didanosine/administration & dosage
- Drug Administration Schedule
- Drug Combinations
- Female
- HIV/genetics
- HIV Infections/ drug therapy/immunology/virology
- HIV Protease Inhibitors/ administration & dosage/adverse effects
- Humans
- Hyperlipidemias/chemically induced
- Male
- Middle Aged
- RNA, Viral/blood
- Reverse Transcriptase Inhibitors/ administration & dosage
- Ritonavir/ administration & dosage/adverse effects
- Saquinavir/ administration & dosage/adverse effects
- Stavudine/administration & dosage
- Thailand
- Time Factors
- Treatment Outcome
- Viral Load
Structure d'affiliation
Groupe de recherche
Citation (format ISO)
ANANWORANICH, Jintanat et al. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. In: Antiviral therapy, 2008, vol. 13, n° 3, p. 375–380.
Fichiers principaux (1)
Article
Identifiants
- PID : unige:7078
- PMID : 18572750
ISSN du journal1359-6535